Pfizer to Seek Approval for Lyme Vaccine Despite Missed Statistical Goal

Pfizer has announced its decision to seek regulatory approval for its Lyme disease vaccine candidate, VLA15, despite the shot not meeting a late-stage trial's statistical goal. The company attributed this outcome to an insufficient number of participants contracting Lyme disease during the study, which impacted the confidence in the results.

Despite the statistical outcome, Pfizer reported that the vaccine demonstrated an over 70% reduction in the rate of infection in vaccinated individuals compared to a placebo group.

Annaliesa Anderson, Pfizer's Chief Vaccines Officer, stated that the observed efficacy is encouraging and supports the vaccine's potential to provide protection against Lyme disease.

Revenue Potential and Strategic Importance

Developed in collaboration with Valneva, the vaccine is not anticipated to be a primary revenue driver for Pfizer. Valneva estimates peak annual sales of $1 billion, in contrast to Pfizer's projected overall revenue of approximately $60 billion this year, which includes over $5 billion from its Covid-19 vaccine.

However, the Lyme vaccine was considered a significant development for Pfizer this year, representing a potential opportunity to introduce the only human vaccine for the disease.

Understanding Lyme Disease and Its Vaccine History

Lyme disease, caused by bacteria primarily transmitted to humans by ticks, can lead to symptoms such as arthritis, muscle weakness, and pain.

Estimates from the Centers for Disease Control and Prevention indicate that approximately 500,000 Americans are diagnosed with or treated for Lyme disease annually.

Despite its prevalence, particularly in the Northeast U.S., a human vaccine is not currently available. A previous human vaccine, LYMErix, was introduced in 1998 by a company that later became GSK but was withdrawn a few years later due to public concerns regarding safety impacting demand. This historical context has influenced the development of subsequent human Lyme vaccines, although several companies currently produce vaccines for dogs.

Navigating Trial Difficulties

Pfizer and Valneva encountered challenges during the Phase 3 trial. In 2023, approximately half of the initial 18,000 participants were removed from the study due to quality concerns associated with the third-party clinical trial site operator, Care Access. The trial ultimately concluded with approximately 9,400 participants.

How VLA15 Works and Its Regimen

The VLA15 vaccine targets the outer surface protein A of the bacteria responsible for Lyme disease. The mechanism involves vaccinated individuals producing antibodies that are subsequently transferred to a tick, which then prevents the bacterium from being transmitted from the tick to the human.

The vaccination regimen consists of three initial doses within the first year, followed by a booster dose in the subsequent year. The companies reported no safety concerns observed during the trial.